Craigavon Cardiac Centre, Southern Health and Social Care Trust, Craigavon, Northern Ireland, UK.
Adv Ther. 2021 May;38(5):2170-2200. doi: 10.1007/s12325-021-01711-z. Epub 2021 Apr 12.
Despite the challenge of a global pandemic, 2020 has been an invaluable year in cardiology research with numerous important clinical trials published or presented virtually at major international meetings. This article aims to summarise these trials and place them in clinical context.
The authors reviewed clinical trials presented at major cardiology conferences during 2020 including the American College of Cardiology, European Association for Percutaneous Cardiovascular Interventions, European Society of Cardiology, Transcatheter Cardiovascular Therapeutics and the American Heart Association. Trials with a broad relevance to the cardiology community and those with potential to change current practice were included.
A total of 87 key cardiology clinical trials were identified for inclusion. New interventional and structural cardiology data included trials evaluating bifurcation percutaneous coronary intervention (PCI) techniques, intravascular ultrasound (IVUS)-guided PCI, instantaneous wave-free (iFR) physiological assessment, new generation stents (DynamX bioadaptor), transcatheter aortic valve implantation (TAVI) in low-risk patients, and percutaneous mitral or tricuspid valve interventions. Preventative cardiology data included new data with proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors (evolocumab and alirocumab), omega-3 supplements, evinacumab and colchicine in the setting of chronic coronary artery disease. Antiplatelet data included trials evaluating both the optimal length of course following PCI and combination of antiplatelet agents and regimes including combination antithrombotic therapies for patients with atrial fibrillation (AF). Heart failure data included the use of sodium-glucose cotransporter 2 (SGLT2) inhibitors (sotagliflozin, empagliflozin and dapagliflozin) and mavacamten in hypertrophic cardiomyopathy. Electrophysiology trials included early rhythm control in AF and screening for AF.
This article presents a summary of key clinical cardiology trials during the past year and should be of relevance to both clinicians and cardiology researchers.
尽管面临全球大流行的挑战，但 2020 年仍是心血管研究中极具价值的一年，众多重要的临床试验已发表或在各大国际会议上虚拟发布。本文旨在总结这些试验并将其置于临床背景下。
作者回顾了 2020 年主要心脏病学会议上提交的临床试验，包括美国心脏病学会、欧洲经皮心血管介入学会、欧洲心脏病学会、经导管心血管治疗和美国心脏协会。纳入的试验与心血管界广泛相关，且具有改变现有实践的潜力。
共确定了 87 项关键心血管临床试验进行纳入。新的介入心脏病学和结构性心脏病数据包括评估分叉经皮冠状动脉介入治疗（PCI）技术、血管内超声（IVUS）指导 PCI、瞬时无波（iFR）生理评估、新一代支架（DynamX 生物适应性支架）、经导管主动脉瓣植入术（TAVI）在低危患者中的应用以及经皮二尖瓣或三尖瓣介入治疗的试验。预防心脏病学数据包括新型前蛋白转化酶枯草溶菌素 9（PCSK9）抑制剂（依洛尤单抗和阿利西尤单抗）、ω-3 补充剂、evinacumab 和秋水仙碱在慢性冠状动脉疾病中的新数据。抗血小板数据包括评估 PCI 后最佳疗程和抗血小板药物联合方案的试验，包括房颤（AF）患者的联合抗栓治疗。心力衰竭数据包括钠-葡萄糖协同转运蛋白 2（SGLT2）抑制剂（索格列净、恩格列净和达格列净）和肥厚型心肌病中 mavacamten 的应用。电生理学试验包括 AF 中的早期节律控制和 AF 的筛查。
本文总结了过去一年的关键临床心脏病学试验，应与临床医生和心脏病学研究人员都相关。
